更新于：2024-12-06
Hydrochlorothiazide/Losartan Potassium
氢氯噻嗪/氯沙坦钾
更新于：2024-12-06
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1995-04-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C29H31Cl2N9O5S2 |
InChIKeyKNOHKZVGSGRPAB-UHFFFAOYSA-N |
CAS号156154-37-9 |
关联
48
项与 氢氯噻嗪/氯沙坦钾 相关的临床试验Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan on Proteinuria in Diabetic Nephropathy Patients
中国健康受试者空腹和餐后单次口服氯沙坦钾氢氯噻嗪片的随机、开放、两序列、四周期、重复交叉设计的生物等效性试验
氯沙坦钾氢氯噻嗪片在健康受试者中随机、开放、单次给药、两制剂、三周期、三序列交叉空腹和高脂餐后状态下生物等效性试验
100 项与 氢氯噻嗪/氯沙坦钾 相关的临床结果
登录后查看更多信息
100 项与 氢氯噻嗪/氯沙坦钾 相关的转化医学
登录后查看更多信息
100 项与 氢氯噻嗪/氯沙坦钾 相关的专利（医药）
登录后查看更多信息
15
项与 氢氯噻嗪/氯沙坦钾 相关的文献（医药）2012-09-01Journal of the renin-angiotensin-aldosterone system : JRAAS4区 · 医学
Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension
4区 · 医学
ArticleOA
作者: Shimizu, Tomohiko ; Kuwano, Takashi ; Mitsutake, Ryoko ; Shiga, Yuhei ; Saku, Keijiro ; Nagata, Itsuki ; Shirotani, Tetsuro ; Fujisawa, Kazuaki ; Miura, Shin-ichiro ; Norimatsu, Kenji ; Uehara, Yoshinari ; Arimura, Tadaaki ; Inoue, Asao ; Matsunaga, Eiyu ; Morii, Joji
Objective::
Many patients still have high blood pressure (BP) after treatment with high-dose angiotensin II type 1 receptor blockers (ARBs) or Preminent® (medium-dose of losartan (50 mg/day)/hydrochlorothiazide (HCTZ) (12.5 mg/day)). Therefore, we analyzed whether Micombi®BP (high-dose telmisartan (80 mg/day)/HCTZ (12.5 mg/day)) could provide better results with regard to efficacy and safety for patients with uncontrolled hypertension.
Methods::
In total, 44 hypertensive patients (22 males, age 71±14 years) who showed uncontrolled BP despite the use of high-dose ARBs or Preminent® were enrolled in this study. We used a changeover design in which the patients were switched from high-dose ARBs or Preminent® to Micombi®BP. We analyzed BP, heart rate (HR), and biochemical parameters before and after treatment for 3 months.
Results::
Systolic BP and diastolic BP significantly decreased (125±15/69±11 mmHg) and 85% of the patients achieved their target BP at 3 months after changeover. Patients who switched from ARBs and those who switched from Preminent® showed similar BP-lowering effects. In addition, the reductions in BP after 3 months in patients with or without chronic kidney disease and in those with or without metabolic syndrome (MetS) were also similar. There were no significant changes in HR during the study period. Although blood levels of potassium, hemoglobin A1c and uric acid (UA) significantly increased after 3 months for all of the patients, none of the patients showed serious adverse effects.
Conclusion::
High-dose telmisartan/HCTZ therapy was associated with a significant reduction in BP and helped patients achieve their target BP.
2012-06-01International journal of cardiology
Congenital absence of the right coronary artery with superdominant left circumflex coronary artery
Letter
作者: Haibo Liu ; Yuping Shi ; Chunming Wang ; Xiaofang Guo ; Sheng Li
A 69-year-old female with atypical chest pain for the previous 2 years was admitted to our hospital. She had had hypertension for 10 years, with long-term oral Hyzaar treatment, and her blood pressure was well controlled. The surface ECG showed normal sinus rhythm and her physical examination was unremarkable. Chest X-ray and two-dimensional echocardiography were normal. She underwent elective coronary angiography with a standard right radial artery approach. Coronary angiography demonstrated a normal looking left main (LM) coronary artery giving rise to left anterior descending (LAD) and a large calibered left circumflex (LCX). The left anterior descending artery was normal but the figure of the left circumflex artery was unique, in that an aberrant branch extended from the distal left circumflex artery, which crossed the crux and continued to the right atrioventricular groove, covering the territory of the right coronary artery (Fig. 1). We were unable to find the ostium of the RCA using a Judkins RCA 4.0 catheter. Injection of contrast medium into the right sinus of Valsalva showed no evidence of RCA originating from the right sinus of the Valsalva. There was no significant stenosis in any of the coronary arteries. Contrast-enhanced 64-slice multidetector cardiac computed tomography also showed absence of the right coronary artery and the extended left circumflex coronary artery to the right coronary artery territory (Fig. 2).
2012-03-01Journal of the renin-angiotensin-aldosterone system : JRAAS4区 · 医学
Effect of fixed-dose losartan/hydrochlorothiazide on brain natriuretic peptide in patients with hypertension
4区 · 医学
ArticleOA
作者: Mitsutake, Ryoko ; Saku, Keijiro ; Uehara, Yoshinari ; Miura, Shin-ichiro ; Shiga, Yuhei ; Inoue, Asao
Objective: Losartan/hydrochlorothiazide (HCTZ) (Preminent®) is a fixed-dose combination of angiotensin II receptor blocker (ARB) and the thiazide diuretic HCTZ that has consistently been shown to be more effective than either losartan or HCTZ. Little is known about the relationship between losartan/HCTZ and blood levels of brain natriuretic peptide (BNP). Methods and results: In this study, 44 patients with hypertension who were being treated with ARB were enrolled. The ARB was changed to losartan/HCTZ because of uncontrolled hypertension. Blood pressure (BP), pulse rate (PR), plasma levels of BNP and other biochemical parameters were analyzed at baseline and 6 and 12 months after the change from ARB. Of the total 44 patients, 33 (75%) achieved the target BP at 12 months. While there was no significant change in PR, systolic and diastolic BP were significantly reduced (−23 ± 3 mmHg and −10 ± 2 mmHg, respectively) during this period. Although there were no significant changes in biochemical parameters, plasma levels of BNP were significantly decreased, especially in patients who had higher levels of BNP at baseline, during this period. Conclusion: Losartan/HCTZ therapy significantly reduced not only BP but also plasma levels of BNP in patients with hypertension. These findings suggest that losartan/HCTZ might have cardioprotective effects in patients with higher levels of BNP.
100 项与 氢氯噻嗪/氯沙坦钾 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 左心室肥大 | 美国 | 2005-04-05 | |
| 脑卒中 | 美国 | 2005-04-05 | |
| 高血压 | 美国 | 1995-04-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | 爱沙尼亚 | 2007-07-11 | |
| 2型糖尿病 | 临床3期 | - | 2001-08-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 15 | 鹹齋壓簾繭窪醖鏇築壓(鹹糧築襯願蓋製壓鬱憲) = 壓壓襯選鏇遞憲蓋襯築 鏇艱艱鑰遞艱鏇積積衊 (鏇糧壓憲範鹽鬱觸鏇範, 願網醖膚簾範選選糧淵 ~ 壓艱廠廠積願簾膚膚膚) 更多 | - | 2011-11-22 | |||
临床4期 | 201 | (Losartan) | 範獵窪糧醖繭衊壓網鬱(廠鹹簾願築鬱鹽窪製簾) = 繭淵構願鬱憲築壓鹽鬱 膚鹽夢廠積鑰製鑰壓壓 (繭鑰廠鹽築簾淵夢網網, 窪簾顧膚壓窪夢積獵網 ~ 觸積窪醖醖鹽淵夢憲醖) 更多 | - | 2010-12-15 | ||
(Carvedilol) | 範獵窪糧醖繭衊壓網鬱(廠鹹簾願築鬱鹽窪製簾) = 製齋獵鹹範憲遞願簾餘 膚鹽夢廠積鑰製鑰壓壓 (繭鑰廠鹽築簾淵夢網網, 夢願窪積積製遞蓋艱糧 ~ 襯壓範窪簾構醖選衊顧) 更多 | ||||||
临床1期 | - | 20 | HCTZ+Losartan (Losartan/HCTZ (Test)) | 糧積構憲壓餘繭餘繭襯(網積網憲鹽構積窪襯衊) = 鑰窪積憲製蓋鹽膚餘醖 鏇廠鹽醖鑰壓淵襯築鑰 (鏇壓獵簾鏇簾鑰選獵餘, 簾構選鑰衊積窪夢衊觸 ~ 鹽窪淵憲淵獵壓壓壓簾) 更多 | - | 2010-09-14 | |
(Hyzaar® (Reference)) | 糧積構憲壓餘繭餘繭襯(網積網憲鹽構積窪襯衊) = 鹽衊遞艱鏇醖積憲構積 鏇廠鹽醖鑰壓淵襯築鑰 (鏇壓獵簾鏇簾鑰選獵餘, 鹽獵鏇積積窪鏇齋網網 ~ 積憲鏇積齋願窪壓鑰鹹) 更多 | ||||||
临床1期 | - | 80 | HCTZ+Losartan (Losartan/HCTZ (Test)) | 膚顧觸餘製構艱願遞窪(餘鹽蓋餘廠選積願構憲) = 糧選衊艱膚鹽餘壓夢蓋 製淵顧衊醖製衊築淵選 (網獵廠膚鹽製鬱壓餘獵, 鏇築積壓衊襯遞構憲積 ~ 餘廠觸製淵築壓齋鑰廠) 更多 | - | 2010-09-14 | |
(Hyzaar® (Reference)) | 膚顧觸餘製構艱願遞窪(餘鹽蓋餘廠選積願構憲) = 範構廠繭鑰製廠繭壓廠 製淵顧衊醖製衊築淵選 (網獵廠膚鹽製鬱壓餘獵, 壓艱遞艱膚廠齋衊願膚 ~ 淵餘製憲艱網獵顧艱艱) 更多 | ||||||
临床3期 | 808 | HCTZ+Losartan (Losartan 50 mg/HCTZ 12.5 mg) | 鹽選鑰壓鑰簾鹹襯製衊(網範衊襯鹹淵網範選觸) = 鹽遞獵餘艱窪衊憲襯選 鬱艱獵選構鬱蓋衊艱網 (構鹹齋壓構簾鏇網觸築, 顧醖醖鏇壓鹹願積淵齋 ~ 衊艱鬱鬱築鏇選鑰構廠) 更多 | - | 2010-04-13 | ||
HCTZ+Valsartan (Valsartan 80 mg/HCTZ 12.5 mg) | 鹽選鑰壓鑰簾鹹襯製衊(網範衊襯鹹淵網範選觸) = 廠築構夢願鬱壓鹹齋襯 鬱艱獵選構鬱蓋衊艱網 (構鹹齋壓構簾鏇網觸築, 憲夢積夢觸窪積廠餘網 ~ 窪醖窪淵餘膚廠繭餘蓋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用